SCHEMBL221915

SCHEMBL221915

CCCCCN1CC(=O)N(CCCCC)C1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 6/20 0.46
FAAH O00519 4/20 0.46
PTGS1 P23219 3/20 0.46
PTGS2 P35354 3/20 0.46
HDAC6 Q9UBN7 1/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
GBA1 P04062 2/20 0.39
CYP19A1 P11511 3/20 0.38
ALDH2 P05091 1/20 0.37
ALDH3A1 P30838 1/20 0.37
PLA2G2A P14555 2/20 0.36
CES1 P23141 1/20 0.36
CDC25A P30304 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27596669 0.94 HDAC6 (0.41) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL10816291 0.91 MGLL (0.40) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL8716133 0.89 MGLL (0.47) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL8716125 0.89 MGLL (0.43) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL19224051 0.88 MGLL (0.49) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL24131214 0.85 HDAC6 (0.38) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL24122401 0.84 HDAC6 (0.36) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL9879851 0.83 MGLL (0.41) MGLLFAAHPTGS1PTGS2HDAC6
SCHEMBL8892280 0.82 MGLL (0.41) MGLLFAAHPTGS1PTGS2ALDH1A1
SCHEMBL13204644 0.82 MGLL (0.47) MGLLFAAHPTGS1PTGS2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US claimed
US-20220186227-A1 Therapeutic Targets for Oncogenic KRAS-Dependent Cancers UNIVERSITY OF MASSACHUSETTS 2022-06-16 US claimed
EP-3946629-A1 THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS University Of Massachusetts (US) 2022-02-09 EP claimed
WO-2020198488-A1 THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS UNIVERSITY OF MASSACHUSETTS (US) 2020-10-01 WO claimed
CN-108658869-A Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy 复旦大学 2018-10-16 CN claimed
EP-3329775-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS Medivation Prostate Therapeutics LLC (US) 2018-06-06 EP claimed
US-9174943-B2 Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2015-11-03 US claimed
CN-103108549-B Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2015-09-09 CN claimed
WO-2015042170-A1 COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS WAYNE STATE UNIVERSITY (US) 2015-03-26 WO claimed
CN-104341396-A Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof SHANGHAI PHARMACEUTICALS HOLDING CO LTD 2015-02-11 CN claimed
EP-2646553-A1 COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS Santaris Pharma A/S (DK) 2013-10-09 EP claimed
US-20130190507-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS MEDIVATION PROSTATE THERAPEUTICS LLC 2013-07-25 US claimed
CN-103108549-A Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS INC 2013-05-15 CN claimed
EP-2538785-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS Medivation Prostate Therapeutics, Inc. (US) 2013-01-02 EP claimed
WO-2012065051-A1 COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS ENZON PHARMACEUTICALS, INC. (US) 2012-05-18 WO claimed
WO-2011106570-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2011-09-01 WO claimed
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US disclosed
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US disclosed
US-5122602-A Optical indicators; medical diagnosis; quantitative analysis; immunoassay MILES INC. (US) 1992-06-16 US disclosed
EP-0383092-A2 Chromogenic merocyanine enzyme substrates Bayer Corporation (US) 1990-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190507-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS BPHL, PTMS, DHPS MGLL 1156/4885FAAH 33/4885PTGS1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.